abstract |
The present invention relates generally to antibodies in the treatment of human disease and reduction of adverse events related thereto. More specifically, the present invention relates to the use of IL1RAP (Interleukin-1 receptor accessory protein) binding proteins (including anti-IL1RAP 0 antagonist antibodies) and their use as treatment and prevention of human disease. |